Identification of New Markers in the Hypereosinophilic Syndrome

Not Applicable

Completed

• Conditions: Hypereosinophilic Syndrome

• Registration Number: NCT01713504
• Lead Sponsor: University Hospital, Lille

Brief Summary

The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06-29
• Study First Submitted: 2012-10-22
• Study First Submitted QC: 2012-10-23
• Study First Posted: 2012-10-24
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Status Verified: 2019-02
• Last Update Submitted: 2019-02-14
• Last Update Posted: 2019-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

• dated and signed informed consent
• virale serology negative or negative result less than 6 months
• virale serology negative for HBV or vaccinated patient
• insured
• virale serology negative or negative result less than 6 months
• negative pregnancy test or female menopause for at least 1 year

Exclusion Criteria

• subject enable adult, under guardianship or under protective measures of justice
• Refusal or inability to give informed consent
• The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of eosinophilia.	one month after patient inclusion

Trial Locations

Locations (1)

CHRU, Hôpital Claude Huriez; 🇫🇷 Lille, Nord, France